The study included more than 165,000 VA patients, 25,000 of whom got the high-dose vaccine during the 2010-2011 flu season, and the rest received the normal vaccine. Researchers tracked those patients’ hospitalizations and deaths.
“The main overall outcome was that we didn’t find a difference between the groups,” said Darren Linkin, MD, one of the study’s authors. “But in a secondary analysis, there appeared to be a strong effect for those 85 or older.”
Despite the study’s findings, its authors noted some limitations, such as its relatively small sample size and the fact that its population was almost all male and had many chronic diseases.
“I don’t think we have the final answers,” on if the high-dose vaccine is necessary, said Diane Richardson, PhD, another study author.
More articles on flu vaccines:
Penalties or incentives for staff flu shot campaign: Which is more effective?
Seasonal flu vaccine protects against avian flu
The Super Bowl effect: Why Seattle and Boston should expect more severe flu seasons
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
